45845PAB4

Intercept Pharmaceuticals Inc

Could not find a ticker for this position, may be a filing error

A biopharmaceutical company that develops medicines for chronic liver diseases, including Ocaliva, a treatment for primary biliary cholangitis, a rare condition where bile ducts progressively damage the liver. Founded in 2002, the company's name reflects its mission to 'intercept' the march of liver disease. The Italian firm Alfasigma acquired it in 2023.

2.00% Convertible Senior Notes due 2026